Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

November 2015

Prior Authorization Required for Rexulti


Effective immediately, Harvard Pilgrim is now covering the medication Rexulti with prior authorization. In July, the U.S. Food and Drug Administration (FDA) approved Rexulti, a drug used to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Rexulti will be covered on the Premium formularies only, at the highest tier (i.e. Tier 3 on the 3-Tier and Tier 4 on the 4-Tier Premium formularies).

Harvard Pilgrim is requiring prior authorization to ensure the cost-effective and appropriate use of Rexulti. Harvard Pilgrim’s Rexulti Clinical Review Criteria detail the requirements that must be met in order to obtain prior authorization. To request prior authorization, please complete the Rexulti Medication Request Form and fax it to MedImpact Healthcare Systems at 888-807-6643. For more information, please refer to the Pharmacy section of Harvard Pilgrim's provider website.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Medicare Advantage Stride (HMO) Updates and Reminders

Prior Authorizations for Medicare Advantage Stride (HMO) via NIA

Medicare Advantage Stride (HMO) Gender Reassignment Services

New 2016 Medicare Advantage Stride (HMO) Benefits

Hospital Discharge Notifications Reminder

ICD-10 Reminder and Provider Support

HCAS Credentialing Best Practices Guide Now Available

Affordable Care Act and Risk Adjustment

CLINICIAN CORNER

Reminder: Referral Procedure Change for Massachusetts Providers

Identifying and Treating Postpartum Depression

Prior Authorization Required for Rexulti

Prior Authorization Required for Zecuity

P&T Committee Updates

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

Reminder: Keep Panel Status Up to Date

Reminder: Bill National Drug Codes (NDC) For Unlisted Drugs

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator